Want to see JP:2927 full AI Analyst Report?
2927 Stock Chart & Stats
¥864.00
-¥2.00(-0.23%)
At close: 4:00 PM EST
¥864.00
-¥2.00(-0.23%)
Day’s Range― - ―
52-Week Range¥810.00 - ¥918.00
Previous CloseN/A
Volume14.60K
Average Volume (3M)18.87K
Market Cap
¥12.17B
Enterprise Value¥26.62K
Total Cash (Recent Filing)¥11.09B
Total Debt (Recent Filing)¥23.76B
Price to Earnings (P/E)10.3
Beta0.43
Next Earnings
Oct 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.19%
Share Statistics
EPS (TTM)96.15
Shares Outstanding14,559,699
10 Day Avg. Volume18,160
30 Day Avg. Volume18,870
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)0.80
Price to Sales (P/S)0.37
P/FCF Ratio-6.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Accelerating Revenue GrowthConsistent acceleration in top-line growth across recent years implies durable demand and successful product or channel execution in health and life-science segments. Over the medium term this supports scale advantages, potential margin expansion, and funding optionality for reinvestment or debt reduction if cash conversion improves.
Improving Operating MarginsA sustained uptick in EBIT margin suggests improving operational efficiency or pricing power rather than a one-off gain. If maintained, higher operating margins increase resiliency to cost shocks, raise free cash flow potential, and improve the company's ability to reinvest in R&D, production capacity, or strategic initiatives.
Rising ROE And Equity BaseImproving ROE alongside a growing equity base indicates better capital efficiency and retention of earnings to support growth. For a business mixing branded products and contract manufacturing, higher ROE can reflect stronger product mix or higher utilization, supporting sustainable shareholder returns if cash generation follows earnings.
Bears Say
Persistent Negative Free Cash FlowMulti-year negative free cash flow signals that accounting profits are not translating into shareholder cash, likely due to investment intensity or working capital strain. Over 2–6 months this constrains capacity to repay debt, sustain dividends, or finance growth internally, increasing reliance on external financing or equity issuance.
Elevated Leverage (~1.60x D/E)A relatively high debt-to-equity ratio reduces financial flexibility and raises vulnerability to margin or interest-rate shocks. With limited free cash flow, elevated leverage increases refinancing and covenant risk, and could force trade-offs between growth spending, dividends, and debt repayment if operating performance softens.
Profitability Below Prior Peak; Margin VolatilityEarnings remain moderate and below historical peaks, indicating volatility in pricing, mix, or costs. Lower, inconsistent margins reduce the firm's ability to generate sustainable cash, amplify the impact of cyclical downturns, and make it harder to deleverage or invest in long-term capabilities without external funding.
AFC-HD AMS Life Science Co., Ltd. News
2927 FAQ
What was AFC-HD AMS Life Science Co., Ltd.’s price range in the past 12 months?
AFC-HD AMS Life Science Co., Ltd. lowest stock price was ¥810.00 and its highest was ¥918.00 in the past 12 months.
What is AFC-HD AMS Life Science Co., Ltd.’s market cap?
AFC-HD AMS Life Science Co., Ltd.’s market cap is ¥12.17B.
When is AFC-HD AMS Life Science Co., Ltd.’s upcoming earnings report date?
AFC-HD AMS Life Science Co., Ltd.’s upcoming earnings report date is Oct 09, 2026 which is in 61 days.
How were AFC-HD AMS Life Science Co., Ltd.’s earnings last quarter?
AFC-HD AMS Life Science Co., Ltd. released its earnings results on Jul 15, 2026. The company reported ¥25.06 earnings per share for the quarter, beating the consensus estimate of N/A by ¥25.06.
Is AFC-HD AMS Life Science Co., Ltd. overvalued?
According to Wall Street analysts AFC-HD AMS Life Science Co., Ltd.’s price is currently Overvalued.
Does AFC-HD AMS Life Science Co., Ltd. pay dividends?
AFC-HD AMS Life Science Co., Ltd. pays a Semiannually dividend of ¥18 which represents an annual dividend yield of 4.19%. See more information on AFC-HD AMS Life Science Co., Ltd. dividends here
What is AFC-HD AMS Life Science Co., Ltd.’s EPS estimate?
AFC-HD AMS Life Science Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AFC-HD AMS Life Science Co., Ltd. have?
AFC-HD AMS Life Science Co., Ltd. has 14,559,699 shares outstanding.
What happened to AFC-HD AMS Life Science Co., Ltd.’s price movement after its last earnings report?
AFC-HD AMS Life Science Co., Ltd. reported an EPS of ¥25.06 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.231%.
Which hedge fund is a major shareholder of AFC-HD AMS Life Science Co., Ltd.?
Currently, no hedge funds are holding shares in JP:2927
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AFC-HD AMS Life Science Co., Ltd.
AFC-HD AMS Life Science Co., Ltd. operates as an original equipment manufacturer of health foods and cosmetics. The company operates through five segments: Healthcare, Pharmaceutical, Department Store, Food and Beverage, and Other Business. The Healthcare segment manufactures, sells, and supplies OEM health foods, such as tablets, capsules, granules, soft drinks, and jelly; and cosmetics, including skin care and hair care products. This segment also operates as an advertising agency focused on planning and producing health information programs, and publishing health information magazines. The Pharmaceutical segment manufactures and sells Chinese herbal medicine, over-the-counter medicines, and generic medicines. The Department Store segment engages in the wholesale of watches, jewelry, and precious metal products. The Food and Beverage segment operates restaurants. The Other Business segment engages in the real estate buying, selling, management, rental, and intermediary business; construction industry; tourism, travel and hotel industry; and school lunch business. AFC-HD AMS Life Science Co., Ltd. was founded in 1969 and is headquartered in Shizuoka, Japan.
Technical Analysis
YUKIGUNI MAITAKE CO., LTD.
―
Nisshin Seifun Group Inc.
―
BASE FOOD Inc.
―
Lacto Japan Co., Ltd.
―
Riken Vitamin Co., Ltd.
―